Tg Therapeutics, Inc.

This is an early-stage safety study testing a new CAR T-cell therapy called azercabtagene zapreleucel for people with B-cell mediated autoimmune disorders like progressive multiple sclerosis. The main goal is to find the safest and most effective dose for future studies by monito…

This study is testing a modified dosing schedule for the multiple sclerosis drug ublituximab. It aims to see if the new schedule is effective at reducing brain lesions and is safe for people with relapsing MS. The trial will also look at how the drug works in people who did not h…

This study aims to understand the real-world safety and effectiveness of the multiple sclerosis drug BRIUMVI. It will follow 500 people with MS who are starting this treatment in their regular care settings. The main goal is to see how well the drug controls relapses and to monit…

This study is testing if giving the MS medication ublituximab as a simple injection under the skin (subcutaneous) works as well as the current method of receiving it through an IV drip. It will involve 360 people with relapsing multiple sclerosis to see if the new method controls…

This study aims to understand if the multiple sclerosis medication BRIUMVI affects pregnancy outcomes. Researchers will compare birth defect rates between pregnant women with MS who take BRIUMVI and those who don't. The registry will follow 728 participants to collect safety info…

This study aims to measure how much of the multiple sclerosis medication BRIUMVI passes into breast milk when breastfeeding mothers take it. Researchers will collect milk samples from 16 participants over 24 hours after their dose to track the drug's levels. The goal is to gather…